Daily non-political popular news in brief.
Breast cancer survival rates improved by novel drug sequence, say researchers
02-12-2007 · EurekAlert!Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the Lancet. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17 percent compared with using tamoxifen alone.
Read more »
Keywords: breast, cancer, survival, rates, improved, novel, drug, sequence, researchers, rate, researcher
« Previous | Next »
Similar news on "Breast cancer survival rates improved by novel drug sequence, say researchers":
- Study finds difference in survival rates among white and black women with advanced breast cancer
06-03-2007 · EurekAlert!
Despite modest overall improvements in breast cancer survival rates for women with advanced disease over the last two decades, the rates for black women have not improved and the difference in life expectancy between white and black women continues to widen, according to researchers at the University of Texas M. D. Anderson Cancer Center.
Similar news · Read more »
- A black and white look at breast cancer mortality
02-21-2007 · EurekAlert!
Researchers suggest a reason for racial disparity in breast cancer survival rates. African and African American women are much less likely to survive breast cancer surgery than their white counterparts and far more likely to get the disease before the menopause. Previous research suggests that those who undergo surgery for the disease before the menopause are more prone to relapse.
Similar news · Read more »
- A new computational technique predicts side-effects of a major cancer drug
11-27-2007 · EurekAlert!
Researchers at the University of California San Diego have developed a novel computer technique to search for the side effects of major pharmaceuticals. The study, reported Nov. 30 in PLoS Computational Biology, relates to a class of drugs known as Select Estrogen Receptor Modulators, which includes tamoxifen, the most prescribed drug in the treatment of breast cancer.
Similar news · Read more »
- Epigenetic drugs, promising for breast cancer treatment
12-20-2006 · EurekAlert!
Worldwide, cancer persists as one of the most important diseases that affect the human being. The knowledge on the molecular bases of cancer generated during the last decades has been successfully translated into small but significant gains in overall cancer survival rates due to better primary prevention measures, improved diagnostic methods and the development of more effective and specific therapies, collectively termed "molecular targeted therapies." In the context of these new forms of treatment, epigenetic or transcriptional cancer therapy is clearly promising.
Similar news · Read more »
- Fat tissue-derived hormone leptin increases e-cadherin expression, obesity-breast cancer link noted
04-29-2007 · EurekAlert!
Being obese increases the risk of breast cancer in post-menopausal women, shortens the time between return of the disease and lowers overall survival rates. Researchers now report evidence on how leptin, a hormone found in fat cells, significantly influences breast cancer development and progression in mice.
Similar news · Read more »
- Penn's Abramson Cancer Center part of major phase III study for myeloma
11-21-2007 · EurekAlert!
Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
Similar news · Read more »
- New biomarker predicts effectiveness of breast cancer drugs
12-07-2006 · EurekAlert!
University of Cincinnati researchers have identified a new way to predict when anti-estrogen drug therapies are inappropriate for patients with hormone-dependent breast cancer.Scientists say these findings could help physicians more accurately predict which tumors will respond to anti-estrogen therapy and improve long-term survival for breast cancer patients.
Similar news · Read more »
- Study finds race affects African American survival of breast cancer
10-23-2006 · EurekAlert!
African American women with breast cancer were more likely to have larger, later-stage tumors that were more difficult to treat and also had lower survival rates than Hispanic and Caucasian women who received the same treatment in two independent series of clinical trials examined by researchers from the University of Texas M. D. Anderson Cancer Center.
Similar news · Read more »
- Novel regulation of the common tumor suppressor PTEN
01-11-2007 · EurekAlert!
PTEN is one of the most commonly mutated tumor suppressor genes. It is an antagonist for many cellular growth, proliferation and survival processes. When mutated or deleted, it causes cancers of the prostate, breast, colon and brain. Researchers led by scientists at Memorial Sloan-Kettering Cancer Center have now identified fundamentally novel regulatory mechanisms of PTEN function. The findings from two related studies are published in the Jan. 12 issue of Cell.
Similar news · Read more »
- Docetaxel given after doxorubicin reduces recurrence
01-08-2008 · EurekAlert!
Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online Jan. 8 in the Journal of the National Cancer Institute.
Similar news · Read more »
